Cover Image
市場調查報告書

Neurocrine Biosciences, Inc.:產品平台分析

Neurocrine Biosciences, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224618
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Neurocrine Biosciences, Inc.:產品平台分析 Neurocrine Biosciences, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月31日 內容資訊: 英文 39 Pages
簡介

Neurocrine Biosciences, Inc.ha是開發為了治療神經系統及內分泌系相關疾病的創新醫藥品之生物醫藥品企業。

本報告提供Neurocrine Biosciences, Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Neurocrine Biosciences, Inc.的基本資料

Neurocrine Biosciences, Inc.概要

  • 主要資訊
  • 企業資料

Neurocrine Biosciences, Inc.:R&D概要

  • 主要的治療範圍

Neurocrine Biosciences, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Neurocrine Biosciences, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Neurocrine Biosciences, Inc.:藥物簡介

  • NBI-69734
  • valbenazine
  • verucerfont
  • 阻礙思覺失調症及異動症的VMAT-2的藥物
  • GPR119受體激動劑
  • GnRHantagonist
  • GPCR受體激動劑
  • 中樞神經系統疾病的小分子

Neurocrine Biosciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Neurocrine Biosciences, Inc.:最近的開發平台趨勢

Neurocrine Biosciences, Inc.:暫停中的計劃

Neurocrine Biosciences, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • tiplimotide
    • indiplon
    • prasterone

Neurocrine Biosciences, Inc.:企業發表

Neurocrine Biosciences, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06875CDB

Summary

Global Markets Direct's, 'Neurocrine Biosciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Neurocrine Biosciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neurocrine Biosciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Neurocrine Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neurocrine Biosciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neurocrine Biosciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate Neurocrine Biosciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neurocrine Biosciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neurocrine Biosciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neurocrine Biosciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurocrine Biosciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neurocrine Biosciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Neurocrine Biosciences, Inc. Snapshot
    • Neurocrine Biosciences, Inc. Overview
    • Key Information
    • Key Facts
  • Neurocrine Biosciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Neurocrine Biosciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Neurocrine Biosciences, Inc. - Pipeline Products Glance
    • Neurocrine Biosciences, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Neurocrine Biosciences, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Phase I Products/Combination Treatment Modalities
      • Neurocrine Biosciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Neurocrine Biosciences, Inc. - Drug Profiles
    • valbenazine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • verucerfont
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize GPR119 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neurocrine Biosciences, Inc. - Pipeline Analysis
    • Neurocrine Biosciences, Inc. - Pipeline Products by Target
    • Neurocrine Biosciences, Inc. - Pipeline Products by Route of Administration
    • Neurocrine Biosciences, Inc. - Pipeline Products by Molecule Type
    • Neurocrine Biosciences, Inc. - Pipeline Products by Mechanism of Action
  • Neurocrine Biosciences, Inc. - Recent Pipeline Updates
  • Neurocrine Biosciences, Inc. - Dormant Projects
  • Neurocrine Biosciences, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • tiplimotide
      • indiplon
      • prasterone
  • Neurocrine Biosciences, Inc. - Company Statement
  • Neurocrine Biosciences, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Neurocrine Biosciences, Inc., Key Information
  • Neurocrine Biosciences, Inc., Key Facts
  • Neurocrine Biosciences, Inc. - Pipeline by Indication, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Stage of Development, 2015
  • Neurocrine Biosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Neurocrine Biosciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Neurocrine Biosciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Neurocrine Biosciences, Inc. - Phase III, 2015
  • Neurocrine Biosciences, Inc. - Phase II, 2015
  • Neurocrine Biosciences, Inc. - Phase I, 2015
  • Neurocrine Biosciences, Inc. - Preclinical, 2015
  • Neurocrine Biosciences, Inc. - Discovery, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Target, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Route of Administration, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Molecule Type, 2015
  • Neurocrine Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Neurocrine Biosciences, Inc. - Recent Pipeline Updates, 2015
  • Neurocrine Biosciences, Inc. - Dormant Developmental Projects,2015
  • Neurocrine Biosciences, Inc. - Discontinued Pipeline Products, 2015
  • Neurocrine Biosciences, Inc., Subsidiaries

List of Figures

  • Neurocrine Biosciences, Inc. - Pipeline by Top 10 Indication, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Stage of Development, 2015
  • Neurocrine Biosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Neurocrine Biosciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Top 10 Target, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Neurocrine Biosciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Neurocrine Biosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top